作者:泰达国际心血管病医院 郑刚
1 双重抗血小板治疗(DAPT)
参考文献
1. Damluji, A.A.; Forman, D.E.; Wang, T.Y.; Chikwe, J.; Kunadian, V.; Rich, M.W.; Young, B.A.; Page, R.L., 2nd; DeVon, H.A.; Alexander, K.P. Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation 2023, 147, e32–e62.
2. Morici, N.; De Servi, S.; De Luca, L.; Crimi, G.; Montalto, C.; De Rosa, R.; De Luca, G.; Rubboli, A.; Valgimigli, M.; Savonitto, S. Management of acute coronary syndromes in older adults. Eur. Heart J. 2022, 43, 1542–1553.
3. Byrne, R.A.; Rossello, X.; Coughlan, J.J.; Barbato, E.; Berry, C.; Chieffo, A.; Claeys, M.J.; Dan, G.-A.; Dweck, M.R.; Galbraith, M.; et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur. Heart J. 2023, 44, 3720–3826.
4. Lawton, J.S.; Tamis-Holland, J.E.; Bangalore, S.; Bates, E.R.; Beckie, T.M.; Bischoff, J.M.; Bittl, J.A.; Cohen, M.G.; DiMaio, J.M.; Don, C.W.; et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022, 145, e4–e17.
5. Salazar, J.A.; Poon, I.; Nair, M. Clinical consequences of polypharmacy in elderly: Expect the unexpected, think the unthinkable. Expert. Opin. Drug Saf. 2007, 6, 695–704.
6. Smaje, A.; Weston-Clark, M.; Raj, R.; Orlu, M.; Davis, D.; Rawle, M. Factors associated with medication adherence in older patients: A systematic review. Aging Med. 2018, 1, 254–266.
7. Maher, R.L.; Hanlon, J.; Hajjar, E.R. Clinical consequences of polypharmacy in elderly. Expert. Opin. Drug Saf. 2014, 13, 57–65.
8. De Servi, S.; Landi, A.; Savonitto, S.; Morici, N.; De Luca, L.; Montalto, C.; Crimi, G.; De Rosa, R.; De Luca, G. Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field. J. Clin. Med. 2023, 12, 2082.
9. Costa, F.; van Klaveren, D.; James, S.; Heg, D.; Räber, L.; Feres, F.; Pilgrim, T.; Hong, M.K.; Kim, H.S.; Colombo, A.; et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 2017, 389, 1025–1034.
10. Montalto, C.; Crimi, G.; Morici, N.; Palmerini, T.; Valgimigli, M.; Savonitto, S.; De Servi, S. Validation and Additive Predictive Value of the Academic Research Consortium-High Bleeding Risk Criteria in Older Adults. Thromb. Haemost. 2021, 121, 1255–1257.
11. Angiolillo, D.J.; Bhatt, D.L.; Cannon, C.P.; Eikelboom, J.W.; Gibson, C.M.; Goodman, S.G.; Granger, C.B.; Holmes, D.R.; Lopes, R.D.; Mehran, R.; et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation 2021, 143, 583–596.
12. Crimi, G.; Morici, N.; Ferrario, M.; Ferri, L.A.; Piatti, L.; Grosseto, D.; Cacucci, M.; Mirizzi, A.M.; Toso, A.; Piscione, F.; et al. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel. J. Am. Heart Assoc. 2019, 8, e010956.
13. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2009, 361, 1045–1057.
14. Wiviott, S.D.; Braunwald, E.; McCabe, C.H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F.-J.; Ardissino, D.; De Servi, S.; Murphy, S.A.; et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007, 357, 2001–2015.
15. Husted, S.; James, S.; Becker, R.C.; Horrow, J.; Katus, H.; Storey, R.F.; Cannon, C.P.; Heras, M.; Lopes, R.D.; Morais, J.; et al. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. Circ. Cardiovasc. Qual. Outcomes 2012, 5, 680–688.
16 Gimbel, M.; Qaderdan, K.; Willemsen, L.; Hermanides, R.; Bergmeijer, T.; de Vrey, E.; Heestermans, T.; Tjon Joe Gin, M.; Waalewijn, R.; Hofma, S.; et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): The randomised, open-label, non-inferiority trial. Lancet 2020, 395, 1374–1381.
17. Szummer, K.; Montez-Rath, M.E.; Alfredsson, J.; Erlinge, D.; Lindahl, B.; Hofmann, R.; Ravn-Fischer, A.; Svensson, P.; Jernberg, T. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome. Circulation 2020, 142, 1700–1708.
18. Bangalore, S. Prasugrel in the Elderly. Circulation 2018, 137, 2446–2449.
19. Savonitto, S.; Ferri, L.A.; Piatti, L.; Grosseto, D.; Piovaccari, G.; Morici, N.; Bossi, I.; Sganzerla, P.; Tortorella, G.; Cacucci, M.; et al. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation 2018, 137, 2435–2445.
20. Roe, M.T.; Goodman, S.G.; Ohman, E.M.; Stevens, S.R.; Hochman, J.S.; Gottlieb, S.; Martinez, F.; Dalby, A.J.; Boden, W.E.; White, H.D.; et al. Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation 2013, 128, 823–833.
21. Koshy, A.N.; Giustino, G.; Sartori, S.; Hooda, A.; Feng, Y.; Snyder, C.; Dasgupta, S.; Kumar, K.R.; Krishnamoorthy-Melarcode, P.; Sweeny, J.; et al. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention 2023, 18, 1244–1253.
22. Capodanno, D.; Angiolillo, D.J. Timing, Selection, Modulation, and Duration of P2Y(12) Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI. JACC Cardiovasc. Interv. 2023, 16, 1–18.
23. Kim, B.K.; Hong, S.J.; Cho, Y.H.; Yun, K.H.; Kim, Y.H.; Suh, Y.; Cho, J.Y.; Her, A.Y.; Cho, S.; Jeon, D.W.; et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020, 323, 2407–2416.
24. Watanabe, H.; Morimoto, T.; Natsuaki, M.; Yamamoto, K.; Obayashi, Y.; Ogita, M.; Suwa, S.; Isawa, T.; Domei, T.; Yamaji, K.; et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022, 7, 407–417.
25. Hahn, J.Y.; Song, Y.B.; Oh, J.H.; Cho, D.K.; Lee, J.B.; Doh, J.H.; Kim, S.H.; Jeong, J.O.; Bae, J.H.; Kim, B.O.; et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): A randomised, open-label, non-inferiority trial. Lancet 2018, 391, 1274–1284.
26. Fujisaki, T.; Kuno, T.; Iwagami, M.; Miyamoto, Y.; Takagi, H.; Deharo, P.; Cuisset, T.; Briasoulis, A.; Panaich, S.; Latib, A. Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2023, 102, 788–802.
27. D’Ascenzo, F.; De Filippo, O.; Gallone, G.; Mittone, G.; Deriu, M.A.; Iannaccone, M.; Ariza-Solé, A.; Liebetrau, C.; Manzano Fernández, S.; Quadri, G.; et al. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): A modelling study of pooled datasets. Lancet 2021, 397, 199–207.
28. Volgman, A.S.; Nair, G.; Lyubarova, R.; Merchant, F.M.; Mason, P.; Curtis, A.B.; Wenger, N.K.; Aggarwal, N.T.; Kirkpatrick, J.N.; Benjamin, E.J. Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2022, 79, 166–179.
29. Dewilde, W.J.; Oirbans, T.; Verheugt, F.W.; Kelder, J.C.; De Smet, B.J.; Herrman, J.P.; Adriaenssens, T.; Vrolix, M.; Heestermans, A.A.; Vis, M.M.; et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013, 381, 1107–1115.
29. Gibson, C.M.; Mehran, R.; Bode, C.; Halperin, J.; Verheugt, F.W.; Wildgoose, P.; Birmingham, M.; Ianus, J.; Burton, P.; van Eickels, M.; et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N. Engl. J. Med. 2016, 375, 2423–2434.
30. Cannon, C.P.; Lip, G.Y.H.; Oldgren, J. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N. Engl. J. Med. 2018, 378, 485–486.
31. Lopes, R.D.; Heizer, G.; Aronson, R.; Vora, A.N.; Massaro, T.; Mehran, R.; Goodman, S.G.; Windecker, S.; Darius, H.; Li, J.; et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N. Engl. J. Med. 2019, 380, 1509–1524.
32. Vranckx, P.; Valgimigli, M.; Eckardt, L.; Tijssen, J.; Lewalter, T.; Gargiulo, G.; Batushkin, V.; Campo, G.; Lysak, Z.; Vakaliuk, I.; et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial. Lancet 2019, 394, 1335–1343. [CrossRef]
33. Menditto, A.; Antonicelli, R. Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? J. Geriatr. Cardiol. 2020, 17, 51–57.
34. Yasuda, S.; Kaikita, K.; Akao, M.; Ako, J.; Matoba, T.; Nakamura, M.; Miyauchi, K.; Hagiwara, N.; Kimura, K.; Hirayama, A.; et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N. Engl. J. Med. 2019, 381, 1103–1113.
35. Casado Arroyo, R.; Polo-Tomas, M.; Roncalés, M.P.; Scheiman, J.; Lanas, A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012, 98, 718–723.
36. Lai, K.C.; Lam, S.K.; Chu, K.M.; Wong, B.C.; Hui, W.M.; Hu, W.H.; Lau, G.K.; Wong, W.M.; Yuen, M.F.; Chan, A.O.; et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002, 346, 2033–2038.
37. Lehault, W.B.; Hughes, D.M. Review of the Long-Term Effects of Proton Pump Inhibitors. Fed. Pract. 2017, 34, 19–23.
38. Rassen, J.A.; Choudhry, N.K.; Avorn, J.; Schneeweiss, S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120, 2322–2329.
39. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; De Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139, e1082–e1143.
40. Gencer, B.; Marston, N.A.; Im, K.; Cannon, C.P.; Sever, P.; Keech, A.; Braunwald, E.; Giugliano, R.P.; Sabatine, M.S. Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomised controlled trials. Lancet 2020, 396, 1637–1643.
41. Lee, S.-H.; Lee, Y.-J.; Heo, J.H.; Hur, S.-H.; Choi, H.H.; Kim, K.-J.; Kim, J.H.; Park, K.-H.; Lee, J.H.; Choi, Y.J. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis. J. Am. Coll. Cardiol. 2023, 81, 1339–1349.
42. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019, 290, 140–205.
43. Densham, E.; Youssef, E.; Ferguson, O.; Winter, R. The effect of statins on falls and physical activity in people aged 65 and older: A systematic review. Eur. J. Clin. Pharmacol. 2024, 80, 657–668.
44. Zhou, Z.; Ryan, J.; Ernst, M.E.; Zoungas, S.; Tonkin, A.M.; Woods, R.L.; McNeil, J.J.; Reid, C.M.; Curtis, A.J.; Wolfe, R. Effect of statin therapy on cognitive decline and incident dementia in older adults. J. Am. Coll. Cardiol. 2021, 77, 3145–3156.
45. Virani, S.S.; Newby, L.K.; Arnold, S.V.; Bittner, V.; Brewer, L.C.; Demeter, S.H.; Dixon, D.L.; Fearon, W.F.; Hess, B.; Johnson, H.M.; et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023, 148, e9–e119.
46. Dahl Aarvik, M.; Sandven, I.; Dondo, T.B.; Gale, C.P.; Ruddox, V.; Munkhaugen, J.; Atar, D.; Otterstad, J.E. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: A systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. 2019, 5, 12–20.
47. Bangalore, S.; Makani, H.; Radford, M.; Thakur, K.; Toklu, B.; Katz, S.D.; DiNicolantonio, J.J.; Devereaux, P.J.; Alexander, K.P.; Wetterslev, J.; et al. Clinical outcomes with β-blockers for myocardial infarction: A meta-analysis of randomized trials. Am. J. Med. 2014, 127, 939–953.
48. Korhonen, M.J.; Robinson, J.G.; Annis, I.E.; Hickson, R.P.; Bell, J.S.; Hartikainen, J.; Fang, G. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2017, 70, 1543–1554.
49. Rossello, X.; Raposeiras-Roubin, S.; Latini, R.; Dominguez-Rodriguez, A.; Barrabés, J.A.; Sánchez, P.L.; Anguita, M.; Fernández Vázquez, F.; Pascual-Figal, D.; De la Torre Hernandez, J.M.; et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur. Heart J. Cardiovasc. Pharmacother. 2022, 8, 291–301.
50. Munkhaugen, J.; Ruddox, V.; Halvorsen, S.; Dammen, T.; Fagerland, M.W.; Hernæs, K.H.; Vethe, N.T.; Prescott, E.; Jensen, S.E.; Rødevand, O.; et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am. Heart J. 2019, 208, 37–46.
51. Kristensen, A.M.D.; Bovin, A.; Zwisler, A.D.; Cerquira, C.; Torp-Pedersen, C.; Bøtker, H.E.; Gustafsson, I.; Veien, K.T.; Thomsen, K.K.; Olsen, M.H.; et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: Study protocol for a randomized controlled trial. Trials 2020, 21, 415.
52. Yndigegn, T.; Lindahl, B.; Mars, K.; Alfredsson, J.; Benatar, J.; Brandin, L.; Erlinge, D.; Hallen, O.; Held, C.; Hjalmarsson, P.; et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N. Engl. J. Med. 2024, 390, 1372–1381.
53. Liu, H.H.; Li, S.; Zhang, Y.; Zhang, M.; Zhang, H.W.; Qian, J.; Dou, K.F.; Li, J.J. Association of β-blocker use at discharge and prognosis of oldest old with acute myocardial infarction: A prospective cohort study. Eur. Geriatr. Med. 2024, 15, 169–178.
54. Zullo, A.R.; Olean, M.; Berry, S.D.; Lee, Y.; Tjia, J.; Steinman, M.A. Patient-Important Adverse Events of β-blockers in Frail Older Adults after Acute Myocardial Infarction. J. Gerontol. A Biol. Sci. Med. Sci. 2019, 74, 1277–1281.
55. Shavadia, J.S.; Holmes, D.N.; Thomas, L.; Peterson, E.D.; Granger, C.B.; Roe, M.T.; Wang, T.Y. Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. Circ. Cardiovasc. Qual. Outcomes 2019, 12, e005103.
56. Ishak, D.; Aktaa, S.; Lindhagen, L.; Alfredsson, J.; Dondo, T.B.; Held, C.; Jernberg, T.; Yndigegn, T.; Gale, C.P.; Batra, G. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart 2023, 109, 1159–1165.
57. Park, C.S.; Yang, H.-M.; Ki, Y.-J.; Kang, J.; Han, J.-K.; Park, K.W.; Kang, H.-J.; Koo, B.-K.; Kim, C.-J.; Cho, M.C. Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of β-blockers: Analysis of data from the KAMIR-NIH registry. Circ. Cardiovasc. Interv. 2021, 14, e010159.
58. Dondo, T.B.; Hall, M.; West, R.M.; Jernberg, T.; Lindahl, B.; Bueno, H.; Danchin, N.; Deanfield, J.E.; Hemingway, H.; Fox, K.A.A.; et al. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J. Am. Coll. Cardiol. 2017, 69, 2710–2720.
59. Holt, A.; Blanche, P.; Zareini, B.; Rajan, D.; El-Sheikh, M.; Schjerning, A.-M.; Schou, M.; Torp-Pedersen, C.; McGettigan, P.; Gislason, G.H.; et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: A Danish, nationwide cohort study. Eur. Heart J. 2021, 42, 907–914.
60. Park, J.J.; Kim, S.H.; Kang, S.H.; Yoon, C.H.; Cho, Y.S.; Youn, T.J.; Chae, I.H.; Choi, D.J. Effect of β-Blockers Beyond 3 Years After Acute Myocardial Infarction. J. Am. Heart Assoc. 2018, 7, e007567.
61. Puymirat, E.; Riant, E.; Aissaoui, N.; Soria, A.; Ducrocq, G.; Coste, P.; Cottin, Y.; Aupetit, J.F.; Bonnefoy, E.; Blanchard, D.; et al. β blockers and mortality after myocardial infarction in patients without heart failure: Multicentre prospective cohort study. BMJ 2016, 354, i4801.
62. Neumann, A.; Maura, G.; Weill, A.; Alla, F.; Danchin, N. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases. Circ. Cardiovasc. Qual. Outcomes 2018, 11, e004356.
63. Kim, J.; Kang, D.; Park, H.; Kang, M.; Park, T.K.; Lee, J.M.; Yang, J.H.; Song, Y.B.; Choi, J.-H.; Choi, S.-H.; et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: Nationwide cohort study. Eur. Heart J. 2020, 41, 3521–3529.
64. Pfeffer, M.A. The Survival and Ventricular Enlargement (SAVE) study: Rationale and perspective. Herz 1993, 18 (Suppl. 1), 430–435.
65. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342, 821–828.
66. Ahn, W.J.; Rha, S.W.; Choi, B.G.; Jeong, M.H. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension. Heart Vessels 2023, 38, 898–908.
67. Yusuf, S.; Teo, K.; Anderson, C.; Pogue, J.; Dyal, L.; Copland, I.; Schumacher, H.; Dagenais, G.; Sleight, P. Effects of the angiotensin receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008, 372, 1174–1183.
68. Pfeffer, M.A.; McMurray, J.J.; Velazquez, E.J.; Rouleau, J.L.; Køber, L.; Maggioni, A.P.; Solomon, S.D.; Swedberg, K.; Van de Werf, F.; White, H.; et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003, 349, 1893–1906.
69. Dickstein, K.; Kjekshus, J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360, 752–760.
70. Pappoe, L.S.; Winkelmayer, W.C. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: Are they underutilized? Drugs Aging 2010, 27, 87–94.
71. Fang, G.; Annis, I.E.; Farley, J.F.; Mahendraratnam, N.; Hickson, R.P.; Stürmer, T.; Robinson, J.G. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction. Pharmacotherapy 2018, 38, 29–41.
72. Abdel-Rahman, E.M.; Alhamad, T.; Reeves, W.B.; Awad, A.S. Management of Diabetic Nephropathy in the Elderly: Special Considerations. J. Nephrol. Ther. 2012, 2, 124.
73. Gray, S.L.; LaCroix, A.Z.; Aragaki, A.K.; McDermott, M.; Cochrane, B.B.; Kooperberg, C.L.; Murray, A.M.; Rodriguez, B.; Black, H.; Woods, N.F. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: Prospective findings from the Women’s Health Initiative Observational Study. J. Am. Geriatr. Soc. 2009, 57, 297–303.
74. Sumukadas, D.; Witham, M.D.; Struthers, A.D.; McMurdo, M.E. Effect of perindopril on physical function in elderly people with functional impairment: A randomized controlled trial. CMAJ 2007, 177, 867–874.
75. Ho, J.K.; Moriarty, F.; Manly, J.J.; Larson, E.B.; Evans, D.A.; Rajan, K.B.; Hudak, E.M.; Hassan, L.; Liu, E.; Sato, N.; et al. Blood Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis. Hypertension 2021, 78, 629–643.
76. Goel, S.S.; Kleiman, N.S.; Zoghbi, W.A.; Reardon, M.J.; Kapadia, S.R. Renin-Angiotensin System Blockade in Aortic Stenosis: Implications Before and After Aortic Valve Replacement. J. Am. Heart Assoc. 2020, 9, e016911.
77. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N. Engl. J. Med. 2003, 348, 1309–132
78. Pfeffer, M.A.; Claggett, B.; Lewis, E.F.; Granger, C.B.; Køber, L.; Maggioni, A.P.; Mann, D.L.; McMurray, J.J.V.; Rouleau, J.L.; Solomon, S.D.; et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N. Engl. J. Med. 2021, 385, 1845–1855.
79. Kwon, O.; Myong, J.P.; Lee, Y.; Choi, Y.J.; Yi, J.E.; Seo, S.M.; Jang, S.W.; Kim, P.J.; Lee, J.M. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation. J. Am. Heart Assoc. 2023, 12, e027824.
80. Moady, G.; Yakubovich, I.; Atar, S. Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study. J. Cardiovasc. Pharmacol. Ther. 2024, 29, 10742484241252474.
本文内容为《门诊》杂志原创内容
转载须经授权并请注明出处。
《门诊》杂志官方微信
长按,识别二维码,加关注